NAMD partnered with the National Association of States United for Aging and Disability (NASUAD), the National Association of State Directors of Developmental Disabilities Services (NASDDDS), and the National Association of State Mental Health Program Directors (NASMHPD) to send a joint letter to the Department of Labor (DOL). The letter outlines the state associations’ concerns with […]

Continue reading

On May 18, NAMD submitted comments to the Health Resources and Services Administration (HRSA) in response to reopened provisions of a proposed rule on the 340B drug discount program. NAMD called for HRSA to maintain its initially proposed “penny pricing” method for 340B drugs, for HRSA to align the 340B ceiling price for new drugs […]

Continue reading

NAMD sent a letter to sponsors of the legislation, “Advancing Care for Exceptional for Kids.” The letter addresses the bill’s underlying structure and implementation issues as well as other opportunities to enhance access to care coordination and high quality services for children with complex medical needs. Read full letter.

Continue reading

On April 29, NAMD sent a letter to leadership of the Senate Finance Committee and the Senate Health, Education, Labor, and Pensions Committee addressing Senators’ efforts to improve the nation’s behavioral health system. In particular, NAMD praised the Committees for their consideration of lifting restrictions on federal Medicaid payments for services provided in Institutions for […]

Continue reading

NAMD Comments on SAMHSA Privacy Rule

NAMD submitted comments to the Substance Abuse and Mental Health Services Administration (SAMHSA) on a proposed rule addressing the confidentiality of substance use disorder information (42 CFR Part 2). In the letter, NAMD requests SAMHSA revise the proposed rule to better support care coordination and information exchange to ensure patient safety and positive outcomes. Read […]

Continue reading

NAMD submitted comments to CMS on the final Medicaid covered outpatient drug rule. In the comments, NAMD calls attention to implementation timeline challenges posed by the rule and provides a suggested approach for handling line extension drugs. Read full letter.  

Continue reading

NAMD sent a letter to U.S. Department of Health and Human Services Secretary Sylvia Mathews Burwell to share the findings of a new value-based purchasing (VBP) report. Based on the report’s findings, the letter requests HHS support Medicaid value-based purchasing in three ways: by promoting Medicaid involvement in federal VBP initiatives, including the prospective payment […]

Continue reading

NAMD responded to a series of questions from the Senate Finance Committee on how to account for value in the pricing and coverage of breakthrough prescription drug therapies. The letter outlines potential policy options for improving the Medicaid Drug Rebate Program and other options to grant states additional tools for managing the impact of these […]

Continue reading